Association between statin use and colorectal cancer risk: A meta-analysis of 42 studies

Cancer Causes and Control

Volumn 25, Issue 2, 2014, Pages 237-249

  Liu, Yanqiong ^a   Tang, Weizhong ^a   Wang, Jian ^a   Xie, Li ^a   Li, Taijie ^a   He, Yu ^a   Deng, Yan ^a   Peng, Qiliu ^a   Li, Shan ^a   Qin, Xue ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Meta analysis; Prevention; Risk; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CANCER RISK; CASE CONTROL STUDY; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG EFFECT; DRUG USE; HUMAN; HYDROPHILICITY; LIPOPHILICITY; LONG TERM CARE; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

CASE-CONTROL STUDIES; COHORT STUDIES; COLORECTAL NEOPLASMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 84893113213     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-013-0326-6     Document Type: Article

References (76)

1. Edwards BK, Ward E, Kohler BA et al (2010) Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:544-573
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11-30
3. O'Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420-1425
4. Boghossian S, Hawash A (2012) Chemoprevention in colorectal cancer - where we stand and what we have learned from twenty year's experience. Surgeon 10:43-52
5. Wong WWL, Dimitroulakos J, Minden MD, Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16:508-519
6. Guruswamy S, Rao CV (2008) Multi-target approaches in colon cancer chemoprevention based on systems biology of tumor cell-signaling. Gene Regul Syst Bio 2:163-176
7. Xiao H, Zhang Q, Lin Y, Reddy BS, Yang CS (2008) Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer 122:2115-2124
8. Blais L, Desgagne A, LeLorier J (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study. Arch Intern Med 160:2363-2368
9. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ (2004) The risk of cancer in users of statins. J Clin Oncol 22:2388-2394
10. Kaye JA, Jick H (2004) Statin use and cancer risk in the general practice research database. Br J Cancer 90:635-637
11. Poynter JN, Gruber SB, Higgins PD et al (2005) Statins and the risk of colorectal cancer. N Engl J Med 352:2184-2192
12. Coogan PF, Smith J, Rosenberg L (2007) Statin use and risk of colorectal cancer. J Natl Cancer Inst 99:32-40
13. Hoffmeister M, Chang-Claude J, Brenner H (2007) Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: A population-based case-control study. Int J Cancer 121:1325-1330
14. Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF (2007) Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: Nested case-control study. Gastroenterology 133:393-402
15. Boudreau DM, Koehler E, Rulyak SJ, Haneuse S, Harrison R, Mandelson MT (2008) Cardiovascular medication use and risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev 17:3076-3080
16. Yang YX, Hennessy S, Propert K, Hwang WT, Sarkar M, Lewis JD (2008) Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf 17:869-876
17. Hachem C, Morgan R, Johnson M, Kuebeler M, El-Serag H (2009) Statins and the risk of colorectal carcinoma: A nested case-control study in veterans with diabetes. Am J Gastroenterol 104:1241-1248
18. Shadman M, Newcomb PA, Hampton JM, Wernli KJ, Trentham-Dietz A (2009) Non-steroidal anti-inflammatory drugs and statins in relation to colorectal cancer risk. World J Gastroenterol 15:2336-2339
19. Robertson DJ, Riis AH, Friis S, Pedersen L, Baron JA, Sorensen HT (2010) Neither long-term statin use nor atherosclerotic disease is associated with risk of colorectal cancer. Clin Gastroenterol Hepatol 8:1056-1061
20. Cheng MH, Chiu HF, Ho SC, Tsai SS, Wu TN, Yang CY (2011) Statin use and the risk of colorectal cancer: A population-based case-control study. World J Gastroenterol 17:5197-5202
21. Samadder NJ, Mukherjee B, Huang SC et al (2011) Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use. Cancer 117:1640-1648
22. Vinogradova Y, Coupland C, Hippisley-Cox J (2011) Exposure to statins and risk of common cancers: A series of nested case-control studies. BMC Cancer 11:409
23. Broughton T, Sington J, Beales IL (2012) Statin use is associated with a reduced incidence of colorectal cancer: A colonoscopy-controlled case-control study. BMC Gastroenterol 12:36
24. Lakha F, Theodoratou E, Farrington SM et al (2012) Statin use and association with colorectal cancer survival and risk: Case control study with prescription data linkage. BMC Cancer 12:487
25. Leung HW, Chan AL, Lo D, Leung JH, Chen HL (2013) Common cancer risk and statins: A population-based case-control study in a Chinese population. Expert Opin Drug Saf 12:19-27
26. Friis S, Poulsen AH, Johnsen SP et al (2005) Cancer risk among statin users: A population-based cohort study. Int J Cancer 114:643-647
27. Jacobs EJ, Rodriguez C, Brady KA, Connell CJ, Thun MJ, Calle EE (2006) Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 98:69-72
28. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S (2007) Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 115:27-33
29. Farwell WR, Scranton RE, Lawler EV et al (2008) The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 100:134-139
30. Flick ED, Habel LA, Chan KA et al (2009) Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: A prospective cohort study. Drugs 69:1445-1457
31. Singh H, Mahmud SM, Turner D, Xue L, Demers AA, Bernstein CN (2009) Long-term use of statins and risk of colorectal cancer: A population-based study. Am J Gastroenterol 104:3015-3023
32. Haukka J, Sankila R, Klaukka T et al (2010) Incidence of cancer and statin usage-record linkage study. Int J Cancer 126:279-284
33. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17:27-36
34. Hippisley-Cox J, Coupland C (2010) Unintended effects of statins in men and women in England and Wales: Population based cohort study using the QResearch database. BMJ 340:c2197
35. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM (2011) Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 71:1763-1771
36. Lee JE, Baba Y, Ng K et al (2011) Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res (Phila) 4:1808-1815
37. Simon MS, Rosenberg CA, Rodabough RJ et al (2012) Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk. Ann Epidemiol 22:17-27
38. Clancy Z, Keith SW, Rabinowitz C, Ceccarelli M, Gagne JJ, Maio V (2013) Statins and colorectal cancer risk: A longitudinal study. Cancer Causes Control 24:777-782
39. Shepherd J, Cobbe SM, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307
40. Sacks FM, Pfeffer MA, Moye LA et al (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335:1001-1009
41. Downs JR, Clearfield M, Weis S et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622
42. Group AOaCftACR (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 288:2998-3007
43. Group LS (2002) Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow-up. Lancet 359:1379-1387
44. Heart Protection Study Collaborative G (2002) MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360:7-22
45. Shepherd J, Blauw GJ, Murphy MB et al (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360:1623-1630
46. Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 364:685-696
47. Strandberg TE, Pyorala K, Cook TJ et al (2004) Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364:771-777
48. Nakamura H, Arakawa K, Itakura H et al (2006) Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 368:1155-1163
49. Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195-2207
50. Kushiro T, Mizuno K, Nakaya N et al (2009) Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension 53:135-141
51. Bulbulia R, Bowman L, Wallendszus K et al (2011) Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: A randomised controlled trial. Lancet 378:2013-2020
52. Limburg PJ, Mahoney MR, Ziegler KL et al (2011) Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention. Cancer Prev Res (Phila) 4:259-269
53. Matsushima T, Nakaya N, Mizuno K et al (2012) The effect of low-dose pravastatin in metabolic syndrome for primary prevention of cardiovascular disease in Japan: A post hoc analysis of the MEGA study. J Cardiovasc Pharmacol Ther 17:153-158
54. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM (2007) Statins and the risk of colorectal cancer: A meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 25:3462-3468
55. Bardou M, Barkun A, Martel M (2010) Effect of statin therapy on colorectal cancer. Gut 59:1572-1585
56. Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283:2008-2012
57. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 339:b2535
58. Greenland S (1987) Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9:1-30
59. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
60. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748
61. Midgette AS, Wong JB, Beshansky JR, Porath A, Fleming C, Pauker SG (1994) Cost-effectiveness of streptokinase for acute myocardial infarction: A combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making 14:108-117
62. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558
63. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560
64. Copas J, Shi JQ (2000) Meta-analysis, funnel plots and sensitivity analysis. Biostatistics 1:247-262
65. Galbraith RF (1988) A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 7:889-894
66. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101
67. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634
68. Moorman PG, Hamilton RJ (2007) Statins and cancer risk - What do we know and where do we go from here? Epidemiology 18:194-196
69. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5:930-942
70. Undela K, Srikanth V, Bansal D (2012) Statin use and risk of breast cancer: A meta-analysis of observational studies. Breast Cancer Res Treat 135:261-269
71. Bansal D, Undela K, D'Cruz S, Schifano F (2012) Statin use and risk of prostate cancer: A meta-analysis of observational studies. PLoS ONE 7:e46691
72. Cui XB, Xie Y, Chen M et al (2012) Statin use and risk of pancreatic cancer: A meta-analysis. Cancer Causes Control 23:1099-1111
73. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W (2013) Statins are associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis. Gastroenterology 144:323-332
74. Hamelin BA, Turgeon J (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19:26-37
75. Lipkin SM, Chao EC, Moreno V et al (2010) Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila) 3:597-603
76. Ioannidis JP, Patsopoulos NA, Evangelou E (2007) Uncertainty in heterogeneity estimates in meta-analyses. BMJ 335:914-916